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Abstract
Platelet-activating factor (PAF) stimulates numerous cell types via the activation of the G-protein 
coupled PAF-receptor (PAFR). PAFR activation not only induces acute pro-inflammatory 
responses, but also delayed systemic immunosuppressive effects by modulating host immunity. 
While enzymatic synthesis and degradation of PAF are tightly regulated, oxidative stressors, such 
as UVB, chemotherapy, and cigarette smoke, can generate PAF and PAF-like molecules in an 
unregulated fashion via the oxidation of membrane phospholipids. Recent studies have 
demonstrated the relevance of the mast cell (MC) PAFR in PAFR-induced systemic 
immunosuppression. The current study was designed to determine the exact mechanism(s), and the 
mediators involved in MC PAFR-mediated systemic immunosuppression. By using a contact 
hypersensitivity model, the MC PAFR was not only found to be necessary, but also sufficient to 
mediate the immunosuppressive effects of systemic PAF. Furthermore, activation of the MC PAFR 
induces MC-derived histamine and prostaglandin E2 (PGE2) release. Importantly, PAFR-mediated 
systemic immunosuppression was defective in mice that lacked MCs, or in MC-deficient mice 
transplanted with histidine decarboxylase- or cyclooxygenase-2-deficient MCs. Lastly, it was 
found that prostaglandins could modulate MC migration to draining lymph nodes. These results 
support the hypothesis that MC PAFR activation promotes the immunosuppressive effects of PAF 
in part through histamine- and PGE2-dependent mechanisms.
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INTRODUCTION
PAF (1-hexadecyl-2-acetyl-glycerophosphocholine) is a soluble lipid mediator of both local 
acute inflammation as well as delayed systemic immunosuppression (1–7). PAF binds a 
single G-protein coupled receptor, PAFR (Ptafr), expressed in many cell types, including: 
platelets, neutrophils, macrophages, dendritic cells, and mast cells (MC) (8–11). PAF 
stimulates the activation of platelets (12–14), induces macrophage, neutrophil and eosinophil 
chemoattraction (15–17), neutrophil extracellular trap release (18), and it has recently been 
discovered to stimulate MC migration to lymph nodes (LN) (19). While the pro-
inflammatory effects of PAF are well characterized, the immunosuppressive effects of PAF 
remain an active area of study. It has been found that exogenous PAF is sufficient to induce 
systemic immunosuppression and that the immunosuppressive effects of UVB are mediated 
by PAF (13). Our laboratory characterized the latter effect in demonstrating that UVB 
generates PAF-like phospholipids (20) that induce systemic immunosuppression. Like UVB, 
other oxidative stressors have demonstrated PAFR-dependent systemic immunosuppression 
including: cigarette smoke, jet fuel, and photodynamic therapy (10, 11).
MCs are long-lived hematopoietic cells that initiate allergic responses upon recognition of 
pathogenic stimuli. MCs store prepackaged vesicles containing inflammatory mediators, 
such as histamine, serotonin, and proteases, which are released following MC activation. 
MCs can also synthesize and secrete cytokines and chemokines, and eicosanoids (21–23). In 
addition to mediator release, MC migration to draining LNs has been found to induce 
immune responses (24). Thus, MCs play an obligate pro-inflammatory role in many immune 
responses.
In contrast to these pro-inflammatory functions, MCs have also been shown to attenuate 
immune responses (25–27). MC IL-10 release has been shown to limit pathology from 
contact dermatitis and chronic UVB irradiation (28). MCs have also been shown to 
contribute to transplant tolerance (29). Additionally, experiments have demonstrated that 
MCs induce Treg differentiation via TGFβ-dependent mechanisms when co-cultured with 
naïve T cells (30), and augment the suppressor activity of myeloid-derived suppressor cells 
(MDSCs) (31, 32). Moreover, MCs fine-tune immune responses by transiently attenuating 
Treg function through histamine receptor H1 activation (33), and inducing Treg recruitment 
by H4 receptor activation (34). Furthermore, MCs attenuate anti-tumor immunity to promote 
skin tumorigenesis (35, 36), and mobilize Tregs and MDSCs in the tumor microenvironment 
(37).
MCs mediate the immunosuppressive effects of UV light, and subcutaneously injected 
histamine, the primary mediator released by MCs, had a similar effect (38). Additionally, 
PAFR expression on MCs was necessary for UVB-induced immunosuppression in a process 
mediated in part by migration of MCs to draining LNs via a CXCR4 signaling axis (19). 
However, the contribution of other non-MC PAFRs is unknown. Lastly, previous studies 
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have shown that cyclooxygenase-2 (COX-2) inhibitors can attenuate the immunosuppressive 
effects of PAF (39, 40), and that the E prostanoid 4 (EP4) receptor is necessary for the 
immunosuppressive effects of UV light (41). As MCs have been demonstrated to generate a 
number of eicosanoids (21–23), the role of MC-derived prostaglandins may be relevant to 
the immunosuppressive mechanisms of PAF. The current studies set out to further delineate 
the link between PAF, MCs, histamine, and COX-2 generated prostaglandin synthesis during 
UVB-induced systemic immunosuppression.
MATERIALS AND METHODS
Reagents and cells
All chemicals were obtained from Sigma–Aldrich (St Louis, MO) unless indicated 
otherwise. COX-2 inhibitor (SC-236) and TGF-β inhibitor (LY364947), and histamine EIA 
kit were obtained from Cayman Chemicals (Ann Arbor, MI). PGE2 EIA was obtained from 
R&D (Minneapolis, MN). qPCR reagents were obtained from Invitrogen (Carlsbad, CA). 
Primers for qPCR were obtained from IDT (Coralville, IA). Antibodies for immunoblot 
analysis were obtained from Abcam (Cambridge, MA; histidine decarboxylase (HDC): 
Rabbit polyclonal #ab37291; COX-2: Rabbit monoclonal #ab62331). Mast cells were 
obtained by culturing murine bone marrow in 10% FBS and IL-3 (10 ng/mL, Peprotech, 
Rocky Hill, NJ) containing IMDM media for 4–8 weeks. Cell cultures contained MC 
populations (FcεR+, c-kit+) greater than 90% as measured by flow cytometry, using 
antibodies from eBioscience (San Diego, CA) and BD Biosciences (San Jose, CA). Cells 
used for in vitro studies were incubated in 1 mL of 10% FBS containing IMDM media 
supplemented with 10 ng/mL of IL-3 in 12 well plates.
Mice
C57BL/6 (WT; Charles River Laboratories, Wilmington, MA) and C57BL/6 KitWsh/Wsh 
(Wsh) (B6.Cg-KitW-sh/HNihrJaeBsmGlliJ, The Jackson Laboratory, Bar Harbor, ME) mice 
were obtained commercially. Ptafr−/− (PAFR KO) (from Prof. T. Shimizu, University of 
Tokyo, Tokyo, Japan) and Hdc−/− (HDC KO) (from Dr. H. Ohtsu, Tohoku University, 
Miyagi, Japan) mice on a C57BL/6 background were kept under pathogen-free conditions. 
Bone marrow from Mcpt5-cre/Ptgs2flox/flox and Ptgs2flox/flox mice for MC transplantation 
were obtained from mice previously described (42, 43). BoyJ mice were provided by the In 
Vivo Therapeutics Core (Indiana University School of Medicine, Indianapolis, IN). Both 
male and female 6–14 week old mice were used for the experiments. All mice were housed 
under specific pathogen-free conditions at the Indiana University School of Medicine or, in 
the case of Mcpt5-cre/Ptgs2flox/flox and Ptgs2flox/flox mice, the University of Pennsylvania. 
All procedures were approved by the Animal Care and Use Committees of respective 
institutions.
Mast cell transplantation and contact hypersensitivity assay
MCs (106) were injected subcutaneously into two rows of four injection sites in a 1 by 2 cm 
area on the shaved dorsal skin of 6–8 wk old Wsh or PAFR KO Wsh mice. After 6 weeks 
post-implantation, mice were used for experiments. For the contact hypersensitivity (CHS) 
assay, mice were either treated on shaved dorsal skin with vehicle, UVB (7.5 kJ/m2 using a 
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Philips F20T12/UV-B lamp), histamine (200 µg s.c.), or CPAF (200 ng i.p.). Five days post-
treatment 25 µL of 0.5% DNFB (in 4:1 acetone/olive oil) was applied to shaved dorsal skin 
at least 2 cm away from the UVB-treated area. Nine days later ear thickness was measured 
using a constant pressure analog thickness gauge (Peacock Model G, 0.4 N, mm × 10−2). 
Subsequently, one ear was treated with 10 µL of 0.5% DNFB while the other ear was treated 
with vehicle. After 24 hours, ear thickness was measured again in these mice. The difference 
in ear swelling between DNFB and vehicle treated ears was normalized to the ear swelling 
in vehicle treated mice (see Figure 1A for details).
Histology
Dorsal skin samples or LNs from mice were formalin fixed for 24 hours before storage in 
ethanol. Specimens were paraffin embedded, sectioned and stained for MCs using acidified 
toluidine blue by the IUSM Histology Core (44). MC numbers were quantified by counting 
ten high power fields (HPF, 600×).
qRT PCR
Total RNA was extracted from treated MCs using the RNAeasy kit (Qiagen). In brief, tissue 
was homogenized in RLT buffer containing 2-mercaptoethanol by pipetting and 
QIAShredder (Qiagen). Purified RNA was quantitated with the NanoDrop 2000 (Thermo 
Fisher Scientific, Lafayette, CO). Reverse transcription of whole RNA was done using 
SuperScript cDNA synthesis kit (Invitrogen) with random hexamers. Quantitative RT-PCR 
was performed for Ptgs2 and Hdc against Gapdh as the endogenous control using the ΔΔCt 
method on a Step One Real-Time PCR machine (Applied Biosystems, Foster City, CA). 
Each assay was performed in triplicate in a 10 µL reaction volume with Taqman Master Mix 
(SA Biosciences, Frederick, MD), 1 ng cDNA, primers at 500 nM and probe at 250 nM.
Flow cytometry
Cells (106) were taken from culture and plated in a 96-well plate in FACS buffer (PBS, 
1%BSA, 0.1% NaN3) for staining. Cells were incubated with Fc Block (BD #553142) for 15 
minutes and then stained with 1:100 or 1:200 dilutions of conjugated primary antibody 
(CD45.1-PE, ckit-APC, CD4-PerCP, FcεR-PE) for 30 minutes. Cells were then washed and 
resuspended in PBS to be stained with viability dye (eFluor 780) at a dilution of 1:1000. 
Cells were then washed and resuspended in FACS buffer to a concentration of about 105 
cells/100 µL for analysis on the Invitrogen Attune Cytometer or the BD LSR II.
Western Blotting and Densitometry
Cells (6×106) were harvested and washed twice with PBS. Cell pellets were then lysed with 
150 µL of lysis buffer (1% Triton-X, 10 mM Tris base, 150 mM NaCl, 1% protease inhibitor 
mixture (Sigma); pH 7.4) and centrifuged for 15 minutes at 400×g at 4°C. Supernatants were 
collected (120 µL), and the protein concentration was measured by BioRad 
spectrophotometry methods. Protein (30–100 µg) with β-mercaptoethanol-containing 
reducing SDS sample buffer was then loaded into a 10% acrylamide gel and run for 45 
minutes under a constant 400 mAmps. Proteins were then transferred onto a nitrocellulose 
membrane for 1 hour at a constant 100 volts at 4°C. The membrane was then cut and 
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incubated with blocking buffer (5% powdered milk, 0.1% Tween-20, in PBS) for 2 hrs at 
room temperature (RT) or overnight at 4°C. Membranes were then incubated with the 
appropriate amount of antibody for 2 hr at RT or overnight at 4°C. Membranes were then 
washed with TBST (20 mM Tris, 150 mM NaCl, 0.1% Tween-20) four times for 5 minutes 
each before incubation with HRP-conjugated secondary antibody (1:5000) for 30 min at RT. 
Membranes were then washed with TBST four times for 5 minutes per wash before 
incubating the membranes with HRP-substrate (Millipore, Billerica, MA) for 1 minute. 
Films were then exposed at serial time points and developed. Radiographs were then 
scanned, digitized, and quantitated by pixel densitometry using ImageJ. Expression by 
densitometry was calculated by (pixel density of gene of interest/GAPDH pixel density) 
normalized to vehicle ratio.
ELISA
Cells (3×106) were plated and treated for the described length of time. Supernatants were 
then collected from suspensions centrifuged at 400 × g for 10 minutes. These supernatants 
were then diluted according to the detectable range of the ELISA (1:10 or 1:100) in media or 
analysis buffer.
Statistics
All statistical calculations were performed using Prism 6. Statistical comparisons are 
described in the figure legend for each experiment. The data represent mean values with 
SEM. Differences were considered statistically significant when the p value was less than 
0.05.
RESULTS
The immunosuppressive effects of UVB are mediated by the MC PAFR
The role of MCs in PAFR-mediated systemic immunosuppression was investigated utilizing 
MC transplants in conjunction with the well-established model of dinitrofluorobenzene 
(DNFB) contact hypersensitivity (CHS) commonly utilized to assess immune competence 
(45–48). The first set of experiments validated a MC transplant model for the use in the CHS 
experiments. This model made use of bone marrow-derived mast cells (BMMCs), which 
were obtained by flushing bone marrow from femurs and tibia of 8–12-week-old mice and 
differentiating the cells in culture with IL-3 (10 ng/mL) supplemented media for 4 weeks. 
Flow cytometry analysis revealed that >90% of the cells were FcεRI+ c-Kit+, suggesting that 
the cells were mature MCs (Supplemental Figure 1A). These mature MCs could then be 
transplanted into the dorsal skin of MC-deficient Wsh mice to reconstitute dermal MCs.
WT and Wsh mice transplanted with MCs prior to a CHS assay showed that CPAF and 
UVB-irradiation attenuate the ear swelling response to DNFB challenge (i.e. 
immunosuppression), compared to vehicle treated mice (Figure 1B). PAFR KO and Wsh 
mice, however, did not demonstrate CPAF or UVB-mediated immunosuppression. As 
expected, MC reconstitution rescued the immunosuppressive phenotype of UVB and CPAF 
in Wsh mice. These findings confirmed that MCs are necessary for UVB/PAFR-mediated 
inhibition of CHS reactions (19, 49–51).
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MC PAFR signaling is required and sufficient for PAFR-mediated immunosuppression
While MCs are necessary for PAFR-mediated immune suppression, it has not been 
determined if MC PAFR is necessary and sufficient for PAF to induce systemic 
immunosuppression. To test this hypothesis, WT, Wsh, or Wsh mice transplanted with WT 
or PAFR KO MCs, were treated with either vehicle or CPAF prior to the CHS protocol. 
While WT MC transplantation to Wsh mice rescued the immunosuppressive ability of 
CPAF, transplantation of PAFR KO MCs failed to rescue this phenotype (Figure 1C). 
Moreover, if WT MCs were transplanted into Wsh mice lacking PAFR (PAFR KO Wsh), 
CPAF treatment exerted a partial, but still significant immunosuppressive effect (Figure 1C). 
To verify that the partially attenuated response in PAFR KO MC transplantation was not due 
to poor transplantation yield, the presence of dermal MCs in these mice was demonstrated 
by Toluidine Blue staining, and MC numbers were found to be similar to control 
(Supplemental Figure 1C). Together, these studies indicate that the MC PAFR is both 
necessary and sufficient to mediate systemic immunosuppression by PAF.
PAF stimulates MC histamine release necessary to induce systemic immunosuppression
MCs are a primary source of the inflammatory mediator, histamine. Next, we wanted to 
determine if PAFR activation induces MC release of histamine, which is necessary for 
systemic immunosuppression. It was found in vitro that CPAF induced BMMC production 
of histidine decarboxylase, the primary synthetic enzyme of histamine, at both the mRNA 
transcript and protein level (Figure 2A and 2B). This coincided with augmented histamine 
release (Figure 2C). These findings indicate that MCs are capable of releasing histamine 
following PAFR activation.
It is known that MC deficient mice do not exhibit UV-induced immunosuppression, but 
subcutaneous injection of histamine elicits an UVB-like immunosuppressive response in WT 
mice suggesting that MC-derived histamine may be a mediator in PAF-induced 
immunosuppression (52). To test this hypothesis, WT, PAFR KO, or Wsh mice were treated 
with vehicle, CPAF, or histamine prior to induction of the CHS response. Unlike CPAF, 
which only inhibited CHS responses in WT mice, histamine treatment inhibited CHS 
responses in all the mouse strains, (Figure 2D). Furthermore, histidine decarboxylase KO 
(HDC KO) mice, which lack the enzyme responsible for histamine biosynthesis, only 
exhibited immunosuppression in response to treatment with histamine, but not CPAF 
(Supplemental Figure 2A). These data collectively show that the production and release of 
histamine are involved in PAF-induced systemic immunosuppression.
To understand whether MC-derived histamine is necessary for PAF-induced 
immunosuppression, MCs derived from WT or HDC KO mice were transplanted into Wsh 
mice prior to CHS induction, and surprisingly, MC HDC was dispensable for PAF-mediated 
immunosuppression (Figure 3A). However, the transfer of HDC KO MCs into PAFR KO 
Wsh mice that lack both MCs and PAFR did not exhibit CPAF-mediated 
immunosuppression of the CHS response, while the transfer of WT MCs into the PAFR KO 
Wsh mouse facilitated the effect (Figure 3B). Non-transplanted Wsh mice responded 
appropriately (Supplemental Figure 2B). These data are consistent with the hypothesis that 
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PAFR signaling in MCs is sufficient to drive immunosuppression via a process involving 
histamine but that MCs are not necessarily the sole source of PAF-induced histamine.
MC COX-2 is necessary for PAF-induced immunosuppression
Previous work has demonstrated the importance of prostaglandins, specifically PGE2 acting 
via its EP4 receptor, in suppression of the immune system by UV light (41). MCs have been 
documented to synthesize and release prostaglandins and other eicosanoids (21–23), but the 
role of MC-derived prostaglandins in PAFR-mediated immunosuppression is unknown. We 
found that CPAF-treatment of BMMCs resulted in increased expression of COX-2 (Figure 
4A, B), and PGE2 release (Figure 4C). As expected, no response was observed when treating 
BMMCs lacking PAFR (Supplemental Figure 1C).
PAFR agonist-induced (e.g. UVB, cigarette smoke, and CPAF) immunosuppression can be 
blocked by COX-2 inhibitors (13, 39, 40, 53). To determine if this COX-2-dependent 
immunosuppressive effect was required for the effects of histamine in this system, WT mice 
were treated with COX-2 inhibitor SC-236 and vehicle, CPAF or histamine, 5 days prior to 
the CHS protocol. COX-2 inhibitors blocked the immunosuppressive effects of both CPAF 
and histamine (Figure 4D). These data are consistent with the hypothesis that COX-2 is 
involved in mediating the immunosuppressive response of PAF, but possibly downstream of 
histamine.
To determine if MC COX-2 expression is required for the immunosuppressive mechanism of 
PAF, a COX-2 deficient MC model was utilized. MCs were derived from the BM of Mcpt5-
cre/Ptgs2flox/flox mice for transplantation into Wsh mice and subsequent CHS experiments. 
This well-characterized model exploits the MC-specific activity of the Mcpt5 promoter to 
generate a cre/flox conditional knock-out of the COX-2 (i.e. Ptgs2) gene only in MCs (42, 
43). BMMCs derived from Mcpt5-cre/Ptgs2flox/flox (COX-2 KO) or control Ptgs2flox/flox 
(COX-2 WT) mice were transplanted into Wsh mice. These mice and WT controls were 
treated with vehicle, CPAF, or histamine, prior to the CHS protocol. Both histamine and 
CPAF induced immunosuppression in both WT mice and Wsh mice transplanted with COX-
WT MCs. In contrast, Wsh mice transplanted with COX-2 KO MCs were resistant to CPAF-
mediated immunosuppression (Figure 5). These findings suggest that MC COX-2 
contributes to the suppressive effects of PAF on the immune system.
PAF-induced MC migration to draining LNs involves COX-2
Recent work in the field has demonstrated that once MCs are activated by UVB or PAF, they 
migrate to draining LNs, and that this migration is necessary for subsequent 
immunosuppression (13, 19, 49, 51). Additionally, PGE2 has been implicated as a mediator 
of UVB-induced immunosuppression (41). Yet, the role of prostaglandins in PAFR-induced 
migration of MCs to draining LNs has not been directly tested. To test if prostaglandins 
mediate PAFR-activated MC migration to LNs, Wsh mice reconstituted with dermal CD45.1 
WT BMMCs were either treated with vehicle or CPAF, and vehicle or COX-2 inhibitor, 
SC-236. Inguinal LN cells were analyzed for c-Kit+/CD45.1+ MCs by flow cytometry 
revealing reduced MC populations in LNs from mice treated with both CPAF and SC-236 
versus CPAF alone, suggesting that COX-2 inhibitors could block the PAFR-mediated 
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migration of MCs to LNs (Figure 6). Histology revealed similar results (Supplemental 
Figure 3). These data are consistent with the hypothesis that MC migration to LNs after 
PAFR activation is regulated by COX-2.
DISCUSSION
PAF and the activation of the MC PAFR have been implicated in mediating the suppressive 
effects of pro-oxidative stressors on the immune response. These oxidative stressors include 
UVB, jet fuel, cigarette smoke, photodynamic therapy, and chemotherapy (39, 50, 52–54). 
Still, the mechanism of this suppression remains to be fully elucidated. While the models 
employed to study these mechanisms have significant precedence in the literature, they have 
potential limitations to consider. In particular, the use of Wsh mice has recently started to 
lose favor due to the fact that aberrant c-kit signaling could ambiguate results, and that these 
mice exhibit abnormal hematopoiesis (55). Moreover, Wsh mice have been found to have 
increased numbers of neutrophils and basophils (56). While significant, we found that this 
model is relevant in that most of this work in the field makes use of Wsh mice. Furthermore, 
newer MC-specific models (e.g. Cpa3-cre) also exhibit their own baseline hematopoietic 
abnormalities (55). There are also reservations with the use of HDC KO mice, as these mice 
have been reported to have decreased numbers of MCs and also demonstrate abnormal 
granule formation (57, 58). As a result of the abnormal granule formation, MCs from HDC 
KO mice may also exhibit abnormal non-histamine storage and release (58). Nevertheless, 
we found this model invaluable for investigating the role of MC-derived histamine.
Recent studies have suggested that Cre-expressing cells, even in the absence of a loxP-
flanked allele, might generate phenotypes including induction of DNA damage and 
inhibition of cell growth (59, 60). We have found no evidence that Mcpt5-cre expression has 
an effect on MC function and observe normal mast cell function with this Cre transgene 
(61). Thus, while this is a caveat in the interpretation of our experiments, it is unlikely to 
impact our conclusions. Also related to this point, while we considered using the Mcpt5-cre/
Ptgs2flox/flox mice for initial CHS experiments, we focused on MC adoptive transfer studies 
for two reasons. First, mucosal MCs still express COX-2 in Mcpt5-cre/Ptgs2flox/flox mice, a 
phenotype which may obscure the role of dermal MC COX-2. Our adoptive transfer system 
allows us to rescue the immunosuppressive effects of PAF by implanting WT MCs and 
isolating the role of a particular MC protein by implanting gene-deficient MCs. Secondly, 
using this adoptive transfer model across several gene-deficient mast cell donors allows us to 
make clearer comparisons between the results of our experiments. These comparisons are an 
important component of our studies allowing us to accurately define pathways in this model.
While it seems that the MC PAFR is necessary and sufficient to mount PAFR-mediated 
systemic immunosuppression, activation of other PAFR expressing cells (e.g. basophils, 
keratinocytes, fibroblasts, endothelial cells) may contribute to reaching the threshold 
necessary to suppress immune responses. The contribution of other PAFR expressing cells is 
highlighted by the role of histamine in the immunosuppressive effects of PAF. Histamine 
appears to be necessary for this mechanism as mice lacking histamine are impervious to the 
immunosuppressive effects of PAF (Supplemental Figure 2). While MCs are the main 
contributor of histamine in the body, MC-derived histamine seems to be dispensable for 
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PAF-induced immunosuppression (Figure 3A). This would suggest that other histamine-
producing cells are involved in this mechanism, such as: basophils, platelets, dendritic cells, 
T cells and macrophages. Still, it seems that this second histamine-producing cell requires 
the presence of PAFR-expressing MCs as neither Wsh or Wsh mice engrafted with PAFR 
KO MCs respond to CPAF (Figure 1C). Furthermore, these secondary histamine-producing 
cells also require PAFR expression as HDC KO MCs rescue the immunosuppressive effects 
of PAF in Wsh but not PAFR KO Wsh (Figure 3). This gives rise to two distinct mechanisms 
for histamine in PAFR-mediated systemic immunosuppression: MC histamine dependent 
and independent pathways. In the latter, the role of the MC may be to recruit secondary 
histamine-producing cells either to the skin or to draining lymph nodes to mount the 
subsequent immunosuppression.
One of the goals of this study was to elucidate the relationship between histamine and 
COX-2 derived prostaglandins in PAFR-mediated systemic immunosuppression. COX-2 has 
been shown to be involved in mediating the immunosuppressive effects of UVB and PAF. A 
proposed mechanism for the involvement of COX-2 in this pathway is the interaction of 
prostaglandins in the regulation of cell chemotaxis, as PGE2 has been previously implicated 
in regulating immune cell chemotaxis (62), and histamine can promote prostaglandin release 
(63, 64). A possible mechanism for the regulation of chemotaxis by prostaglandins is 
through the regulation of chemokine ligand/receptors. One such example of prostaglandins 
mediating MC migration is the ability of PGE2 to induce CXCL12, the CXCR4 ligand, 
expression in endothelial cells (19). The Ullrich laboratory has shown that MC PAFR 
activation upregulates CXCR4 expression in MCs and promotes the obligate chemotaxis to 
draining LNs necessary to mediate immunosuppression (19). Still, it remains to be 
elucidated how the CXCR4-CXCL12 chemokine gradient is established to facilitate PAF-
induced MC migration to draining LNs.
The work presented herein suggests that COX-2 and histamine mediate the 
immunosuppressive effects of PAF (Theoretical Model Figure 7). It appears that a “pro-
inflammatory” threshold must be reached before subsequent immunosuppression ensues, 
where COX-2-derived prostaglandins and histamine contribute to the pro-inflammatory 
“cytokine storm” activation energy. It would be of particular interest to identify the site of 
action of histamine and prostaglandins. The current evidence in this work gives rise to two 
hypotheses for how MCs may be mediating immune suppression: first, either by direct 
interactions with lymphocytes in draining LNs following CXCR4-dependent MC migration 
to LNs, or second by MC release of mediators in the skin that act locally or travel via 
lymphatics to affect T cell activation in draining LNs. As mentioned before, MC migration 
to draining LNs is necessary to mediate systemic immunosuppression, and migration is 
mediated via CXCR4 chemotaxis following MC PAFR activation (19, 49, 51). It has also 
been shown that MC-derived particles can travel via lymphatic vessels to signal at distant 
LNs (65). This could be important because histamine and prostaglandins released following 
MC PAFR activation could travel to draining LNs to influence T cell activity.
In summary, these studies indicate that systemic immunosuppression induced by PAFR 
activation is mediated by the MC PAFR. Moreover, MC COX-2 appears to play an important 
role in this process. Given that systemic PAFR activation is associated with multiple 
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environmental pro-oxidative stressors, from chemotherapy and radiation therapy to cigarette 
smoking and UVB radiation, an understanding of this process could result in potential 
therapeutics to address this potentially unwanted immunosuppression.
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Figure 1. The MC PAF-R is necessary and sufficient to attenuate CHS
A. Model of CHS experiment: MCs (106) were injected subcutaneously into two rows of 
four injections sites in a 1 by 2 cm area on the shaved dorsal skin of 6–8 wk old Wsh or 
PAFR KO Wsh mice. After 6 weeks post-implantation, mice were used for experiments. 
Mice were then treated with CPAF (250ng, i.p.) or vehicle (PBS, i.p.), histamine (200 µg, 
s.c.) or UVB (7.5kJ/m2) on shaved dorsal skin. Five days later mice are sensitized to DNFB 
by applying 25 µL of 0.5% DNFB in acetone:olive oil (4:1) on shaved dorsal skin. Nine days 
later ears are measured, one ear of the mice was treated with 0.5% DNFB, whereas the other 
was treated with vehicle. Ear thickness was measured 24 hours later. Change in ear thickness 
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is the difference in ear thickness between right and left ears. B. Groups of n= 8–12 WT, 
PAFR KO, Wsh, or Wsh mice reconstituted with WT MC were treated with UVB, CPAF, or 
vehicle 5 days prior to initiation of CHS experiment. C. Groups of n= 8–9 WT, Wsh, Wsh 
mice reconstituted with WT or PAFR KO MC, or PAFR KO Wsh mice reconstituted with 
WT MC, were treated with CPAF or vehicle 5 days prior to initiation of CHS experiment. 
Data shown as ear thickness measurements normalized to WT vehicle treated mice. Figure 
representative of two separate experiments. * Denotes statistically significant differences 
(p<0.05) in Vehicle vs. treatment (CPAF or UVB) for each group. Statistical significance 
was determined using two-way ANOVA and the post-hoc Sidak’s method. Error bars show 
SEM.
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Figure 2. MC PAFR activation induces the release of immunosuppressive histamine
A.) Relative expression of hdc mRNA to gapdh was measured by qRT-PCR following 
treatment of MCs with either vehicle, or 100nM CPAF for 4–24hrs. Expression is depicted 
as fold increase over vehicle following CPAF treatment. Dashed line represent 1-fold 
change. Figure representative of three independent experiments. B.) Lysates from MCs 
treated with CPAF or 1 mM ionophore A23187/100 nM PMA for 24 hours were 
immunoblotted for HDC. Quantitation represents mean fold HDC expression over vehicle-
treated cells. Blot is representative of three experiments. C.) Histamine release in 
supernatants from cells treated with vehicle, 100nM CPAF or 3µg/ml αFcεR Ab for 1 hour 
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was measured by EIA. Figure depicts the mean of three separate experiments. D.) Groups of 
n= 8–12 WT, PAF-R KO or Wsh mice were treated with histamine (200 µg s.c.), CPAF (250 
ng i.p.), or vehicle 5 days prior to DNFB sensitization. Mice were challenged with DNFB on 
Day 9 post-challenge and ear thickness was measured 24 hours later. Data shown as ear 
thickness measurements normalized to vehicle treated mice. Figure is representative of three 
separate experiments. * Denotes statistically significant differences (p<0.05) in Vehicle vs. 
treatment (CPAF or histamine) for each group. Statistical significance determined using two-
way ANOVA (A and D) or one-way ANOVA (B and C) and the post-hoc Sidak (A–C) or 
Holm-Sidak (D) method, with alpha=5%. Error bars represent SEM.
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Figure 3. MC-derived histamine promotes but is not necessary for PAFR inhibition of CHS 
response
WT or HDC KO MCs were transplanted into the dorsal skin of Wsh (A) or PAFR KO/Wsh 
(B) mice. Groups of n= 5–8 mice along with WT were treated with vehicle, CPAF i.p. or 
histamine s.c. 5 days before sensitization to DNFB for CHS assay. Mice were challenged 
with DNFB on Day 9 post-challenge and ear thickness was measured 24 hours later. Data 
shown as ear thickness measurements normalized to vehicle treated mice. Figures A and B 
representative of two independent experiments each. * Denotes statistically significant 
differences (p<0.05) in Vehicle vs. treatment (CPAF or histamine) for each group. Statistical 
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significance determined using two-way ANOVA and the post-hoc Holm-Sidak method, with 
alpha=5%. Error bars represent SEM.
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Figure 4. COX-2 plays a role in PAFR-mediated immunosuppression and is regulated by PAF 
and histamine
A.) Relative expression of ptgs2 mRNA to gapdh was measured by qRT-PCR following 
treatment of MCs with either vehicle, or 100nM CPAF for 4–24hrs. Expression is depicted 
as fold increase over vehicle following CPAF treatment. Dashed lines represent 1-fold 
change. Figure representative of three independent experiments. B.) Lysates from MCs 
treated with CPAF or 1 mM ionophore A23187/100 nM PMA for 24 hours were 
immunoblotted for COX-2 protein. Quantitation represents fold COX-2 expression over 
vehicle-treated cells. Blot is representative of three experiments. C.) PGE2 release in 
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supernatants from cells treated with vehicle, CPAF or Ionophore/PMA for 24hrs were 
measured by EIA. D.) Groups of n= 6–8 WT mice were treated with vehicle or SC-236 (200 
ng), and vehicle, histamine (200 µg s.c.),or CPAF (250 ng i.p.) 5 days before sensitization to 
DNFB for CHS assay. Mice were challenged with DNFB on Day 9 post-challenge and ear 
thickness was measured 24 hours later. Data shown as ear thickness measurements 
normalized to vehicle treated mice. Figure is representative of three separate experiments. * 
Denotes statistically significant differences (p<0.05) in Vehicle vs. treatment (CPAF or 
histamine) for each group. Statistical significance determined using two-way ANOVA (A) or 
one-way ANOVA (B-D) and the post-hoc Sidak (A and B) or Dunnett’s (C and D) method, 
with alpha=5%. Error bars represent SEM.
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Figure 5. MC COX-2 is necessary for PAFR mediated immunosuppression
WT (ptgs2flox/flox) or COX-2 KO (mcpt5-cre/ptgs2flox/flox) MCs were transplanted into the 
dorsal skin of Wsh mice. Groups of n= 7–10 mice along with WT were treated with vehicle, 
CPAF i.p. or histamine s.c. 5 days before sensitization to DNFB for CHS assay. Mice were 
challenged with DNFB on Day 9 post-challenge and ear thickness was measured 24 hours 
later. Data shown as ear thickness measurements normalized to vehicle treated mice. Figure 
representative of two separate experiments. * Denotes statistically significant differences 
(p<0.05) in in Vehicle vs. treatment (CPAF or histamine) for each group. Statistical 
significance determined using two-way ANOVA and the post-hoc Holm-Sidak method, with 
alpha=5%. Error bars represent SEM.
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Figure 6. SC-236 blocks MC migration to LNs
CD45.1 BOYJ BMMCs (106) were transplanted into the dorsal skin of Wsh mice. Groups of 
n= 3 mice in each group were then treated with vehicle or CPAF, and vehicle or SC-236. 
Inguinal LNs were harvested 24 hrs later and filtered to make a single cell suspension. Cells 
were stained (CD45.1-PE, ckit-APC, CD4-PerCP, viability) and analyzed by flow cytometry. 
A. Figure depicts representative dot plots of ckit+ CD45.1+ CD4− cells. B. Mean total 
number of MCs per LN were calculated. * Denotes statistically significant differences 
(p<0.05) in the comparisons shown by the black bars. The data represent mean +/− SEM of 
n = 9 in each group pooled from three independent experiments. Statistical significance 
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determined using one-way ANOVA and the post-hoc Holm-Sidak method for multiple 
corrections, with alpha=5%.
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Figure 7. Schematic showing proposed mechanism for PAF-R-induced immunosuppression
UVB initiates a cascade of events resulting in immunosuppression over the course of 5–15 
days for the duration of CHS experiments (for detailed timeline refer to Fig 1A). UVB 
irradiation of the skin leads to the formation of PAFR agonists in the skin (20). MC PAFR 
activation stimulates PGE2 and histamine release. PAFR activation in keratinocytes and 
fibroblasts have been shown to induce COX-2 expression (66). Additionally, histamine-
stimulated keratinocytes release PGE2 (64). Subsequently, PGE2 may possibly activate MCs 
via autocrine and paracrine mechanisms involving upregulation of chemokine receptor 
CXCR4 to induce MC migration to draining lymph nodes over the course of 24 hours. In the 
LNs, MCs may induce systemic immunosuppression via production of cytokines like TGFβ 
that favor the differentiation of Tregs. This immunosuppression is mediated by Tregs (39), 
possibly via a decrease in CTL and Th1 populations, resulting in decreased CHS reactions.
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